摘要
目的探讨固定剂量复合剂异福酰胺胶囊和异福胶囊抗结核疗效及安全性。方法将187例初治痰涂片阳性肺结核患者,双盲随机分为治疗组93例和对照组94例进行短程化疗。结果治疗组和对照组2个月末痰菌阴转率分别达85.4%(76例)和83.9%(73例);满疗程痰菌阴转率分别为97.8%(87例)和97.7%(85例);胸部X线病灶,治疗组显效率62.9%(56例),对照组62.1%(54例);治疗组有效率98.9%(88例),对照组97.7%(85例);疗程结束时治疗组空洞闭合率为92.9%(26/28),对照组空洞闭合率为92%(23/25);不良反应发生率分别为治疗组11.8%(11/93)、对照组14.9%(14/94)。结论抗结核固定剂量复合剂异福酰胺胶囊和异福胶囊是一种疗效高、安全、方便、能减少耐药性发生的抗结核制剂。
Objective To discuss the anti- tuberculosis efficacy and safety on fixed dose combination（ FDC）Rifampin Isoniazid and Pyrazinamide capsules,and Rifampin and Isoniazid Capsules. Methods Take 187 patients with newly diagnosed patients with smear positive pulmonary tuberculosis,double blinded and randomly divided into the treatment group of 93 cases and control group with 94 cases of short course chemotherapy. Results The treatment group and the control group of 2 sputum negative conversion rate were 85. 4%（ 76 cases）and 83. 9%（ 73 cases）; over the course of the sputum negative conversion rate was 97. 8%（ 87 cases） and97. 7%（ 85 cases）; chest X- ray lesions,the efficiency of the treatment group 62. 9%（ 56 cases）,control group 62. 1%（ 54 cases）; the effective rate of treatment group 98. 9%（ 88 cases）,control group 97. 7%（ 85 cases）; the end of treatment,cavity closure rate was 92.9%（ 26/28）,the control group the cavity closure rate was 92%（ 23 /25）; the incidence rate of adverse reaction was 11. 8%（ 11 /93） in the treatment group,the control group 14. 9%（ 14 /94）. Conclusions TB fixed dose combination Rifampin Isoniazid and Pyrazinamide capsules,and Rifampin and Isoniazid Capsules is a highly effective,safe,convenient taking,can reduce the occurrence of resistance to anti tuberculosis drugs.
出处
《医学动物防制》
2014年第7期800-801,803,共3页
Journal of Medical Pest Control
关键词
结核病
固定剂量复合剂
疗效观察
Tuberculosis
Fixed dose combination
Curative effect observation
